Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: low‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA probably leads to lower moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS probably leads to higher pneumonia: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in pneumonia: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS leads to lower moderate to severe exacerbations: high‐risk population compared with LABA (high certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS probably leads to lower moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review